Casdin Capital is a New York-based fundamental research investment firm focused on the life sciences and healthcare industry, founded in 2012 by Eli Casdin. The firm manages over $2 billion in assets and operates across a long-short public equity fund and private venture investments from early stage to crossover. It employs PhD scientists and MDs alongside financial professionals.

Casdin participated as an existing investor in Beacon Biosignals' $86M Series B round in November 2025. It previously invested in Blackrock Neurotech. Its broader portfolio of 250+ investments spans genomics, biotechnology, synthetic biology, digital health, and life science tools, including major positions in companies like 23andMe, Adaptive Biotechnologies, Recursion Pharmaceuticals, and Ginkgo Bioworks.

Casdin is US-focused with broad life sciences coverage. For neurotech, it is most relevant to companies at the intersection of data science, diagnostics, and clinical neuroscience rather than pure device plays.